Ensitrelvir PEP was safe and effective for COVID-19 prevention among household contacts when administered after the onset of symptoms in an index patient.

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Spotlight reports on this and some of the ...

For household contacts of individuals with COVID-19, taking ensitrelvir within 72 hours of symptoms is effective at ...

The trial conducted in Durban, South Africa, showed that 20 per cent of participants remain off ART and are virally suppressed after one-and-a-half years, according to a press statement from the ...

Previous research has suggested an increased risk for neuropsychiatric symptoms in people living with HIV who are being ...

Increasing HPV vaccination rates could help decrease the number of cancer cases “attributable to HIV,” according to data from ...

Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.

The Conference on Retroviruses and Opportunistic Infections 2025 (CROI) featured multiple sessions that focused on breaking research and treatments.

Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.

SAN FRANCISCO -- Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence ...